China Food For Special Medical Purpose Market Size, Share & Trends Analysis Report By Route Of Administration (Oral, Enteral), By Product (Pills, Powder, Liquid), By Application, By Modules, By Sales Channel, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Market Size & Trends
The China food for special medical purpose market size was estimated at USD 2.27 billion in 2024 and is expected to grow at a CAGR of 6.58% from 2025 to 2030. The growth is attributed to the aging population, increasing prevalence of chronic diseases, rising malnutrition rates, and supportive regulatory frameworks. These factors contribute to the expanding demand for specialized nutritional products tailored to meet the unique needs of various patient groups. For instance, in July 2022, Nestl? introduced China's first food for special medical purpose (FSMP) specifically designed for patients with tumor-related conditions, following a five-year approval process by Chinese regulatory authorities.
The rising prevalence of chronic diseases such as hypertension, diabetes, and cancer is another significant driver. These conditions often lead to complications such as malnutrition and weight loss, increasing the need for specialized nutritional interventions. FSMPs formulated to support individuals with chronic illnesses help manage symptoms, improve quality of life, and reduce healthcare costs associated with malnutrition and related complications.
The Chinese government maintained the regulatory framework for Foods for Special Medical Purposes (FSMPs), with growing advocacy for future reimbursement coverage. The regulatory oversight for FSMPs is managed by the National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), facilitating product approvals and supporting market growth. As of September 2024, China had 206 registered FSMPs; of these, 174 are domestically produced, while 32 are imported, with domestically produced products significantly outnumbering imported ones. Among the approved products, 153 are powdered, and the remaining 53 are liquid.
A total of 66 FSMP products were approved for registration in 2024, originating from 17 different provinces and regions across China. Jiangsu, Shandong, and Heilongjiang emerged as the top three contributors, with 21, 10, and 6 approvals, respectively. These figures represent 32%, 15%, and 9% of the total registrations for the year.
The COVID-19 pandemic impacted China’s FSMP market by accelerating the demand for clinical nutrition products amid increased health awareness and medical needs. During the pandemic, the focus on patient care for vulnerable populations, such as those with chronic illnesses or compromised immunity, increased the reliance on specialized nutritional support to aid recovery and improve health outcomes. Several sectors faced economic downturns and cautious consumer spending, and healthcare and nutrition-related industries, including FSMP, saw growing attention due to their critical role in disease management and prevention. In addition, the pandemic expedited digital transformation and modernization in China’s healthcare system, facilitating better distribution, remote consultations, and awareness of FSMP products. The challenges, such as disrupted supply chains and regulatory adjustments, influenced market dynamics. Overall, COVID-19 catalyzed increased clinical nutrition adoption in China, setting the stage for sustained growth in the FSMP market as part of the country’s broader healthcare recovery and modernization efforts.
China Food For Special Medical Purpose Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the China food for special medical purpose (FSMP) market report based on route of administration, product, application, modules, and sales channel.
Danone (Nutricia)
Nestl?
Abbott
Fresenius Kabi AG
Mead Johnson (Reckitt Benckiser)
Maifu Nutrition technology
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
H&H Group (Biostime)
Synutra, Inc.
Beingmate global
Taicang Puyuan Pharmaceutical Co.
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Ainuo Instrument Co., Ltd.
Kunyu Health Pharmaceutical Jiangsu Co., Ltd.
Shijiazhuang Junlebao Taixing Dairy Co., Ltd.
Jiangsu Dongze Special Medical Food Co., Ltd.
Heilongjiang Feihe Dairy Co., Ltd.
Market Size & Trends
The China food for special medical purpose market size was estimated at USD 2.27 billion in 2024 and is expected to grow at a CAGR of 6.58% from 2025 to 2030. The growth is attributed to the aging population, increasing prevalence of chronic diseases, rising malnutrition rates, and supportive regulatory frameworks. These factors contribute to the expanding demand for specialized nutritional products tailored to meet the unique needs of various patient groups. For instance, in July 2022, Nestl? introduced China's first food for special medical purpose (FSMP) specifically designed for patients with tumor-related conditions, following a five-year approval process by Chinese regulatory authorities.
The rising prevalence of chronic diseases such as hypertension, diabetes, and cancer is another significant driver. These conditions often lead to complications such as malnutrition and weight loss, increasing the need for specialized nutritional interventions. FSMPs formulated to support individuals with chronic illnesses help manage symptoms, improve quality of life, and reduce healthcare costs associated with malnutrition and related complications.
The Chinese government maintained the regulatory framework for Foods for Special Medical Purposes (FSMPs), with growing advocacy for future reimbursement coverage. The regulatory oversight for FSMPs is managed by the National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), facilitating product approvals and supporting market growth. As of September 2024, China had 206 registered FSMPs; of these, 174 are domestically produced, while 32 are imported, with domestically produced products significantly outnumbering imported ones. Among the approved products, 153 are powdered, and the remaining 53 are liquid.
A total of 66 FSMP products were approved for registration in 2024, originating from 17 different provinces and regions across China. Jiangsu, Shandong, and Heilongjiang emerged as the top three contributors, with 21, 10, and 6 approvals, respectively. These figures represent 32%, 15%, and 9% of the total registrations for the year.
The COVID-19 pandemic impacted China’s FSMP market by accelerating the demand for clinical nutrition products amid increased health awareness and medical needs. During the pandemic, the focus on patient care for vulnerable populations, such as those with chronic illnesses or compromised immunity, increased the reliance on specialized nutritional support to aid recovery and improve health outcomes. Several sectors faced economic downturns and cautious consumer spending, and healthcare and nutrition-related industries, including FSMP, saw growing attention due to their critical role in disease management and prevention. In addition, the pandemic expedited digital transformation and modernization in China’s healthcare system, facilitating better distribution, remote consultations, and awareness of FSMP products. The challenges, such as disrupted supply chains and regulatory adjustments, influenced market dynamics. Overall, COVID-19 catalyzed increased clinical nutrition adoption in China, setting the stage for sustained growth in the FSMP market as part of the country’s broader healthcare recovery and modernization efforts.
China Food For Special Medical Purpose Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the China food for special medical purpose (FSMP) market report based on route of administration, product, application, modules, and sales channel.
- Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Enteral
- Product Outlook (Revenue, USD Million, 2018 - 2030)
- Pills
- Powder
- Liquid
- Others (semisolid, semiliquid)
- Application Outlook (Revenue, USD Million, 2018 - 2030)
- Chronic Kidney Disease
- Minimal Hepatic Encephalopathy
- Chemotherapy Induced Diarrhea
- Pathogen Related Infections
- Diabetic Neuropathy
- ADHD
- Depression
- Alzheimer's Disease
- Nutritional Deficiency
- Orphan Diseases
- Tyrosinemia
- Eosinophilic Esophagitis
- Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES))
- Phenylketonuria (PKU)
- Maple syrup urine disease (Maple syrup urine disease (MSUD))
- Homocystinuria
- Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc.)
- Wound Healing
- Chronic Diarrhea
- Constipation Relief
- Protein Booster
- Dysphagia
- Pain Management
- Parkinson's Disease
- Epilepsy
- Other Cancer related treatments
- Severe Protein Allergy
- Cancer
- Cachexia
- Other (debilitating conditions, COPD, etc.)
- Modules Outlook (Revenue, USD Million, 2018 - 2030)
- Amino Acid Module
- Protein Module
- Vitamin & Mineral Modules
- Fatty Acid based Modules
- Carbohydrate Modules
- Fiber Modules
- Ketogenic Modules
- Peptide based Modules
- Hypoallergic Modules
- Others (Electrolyte Module, etc.)
- Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
- DTC Sales Channel
- Online Sales
- Retail Sales
- Institutional Sales
- Hospitals
- Others (Long-term Care Facilities, etc.)
Danone (Nutricia)
Nestl?
Abbott
Fresenius Kabi AG
Mead Johnson (Reckitt Benckiser)
Maifu Nutrition technology
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
H&H Group (Biostime)
Synutra, Inc.
Beingmate global
Taicang Puyuan Pharmaceutical Co.
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Ainuo Instrument Co., Ltd.
Kunyu Health Pharmaceutical Jiangsu Co., Ltd.
Shijiazhuang Junlebao Taixing Dairy Co., Ltd.
Jiangsu Dongze Special Medical Food Co., Ltd.
Heilongjiang Feihe Dairy Co., Ltd.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.6. Research Assumption
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. Objectives
1.8.1. Objective - 1
1.8.2. Objective - 2
1.8.3. Objective - 3
1.9. List of Secondary Sources
1.10. List of Secondary Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. China FSMP Market
2.1.1. Market Snapshot
2.1.2. Segment Snapshot
2.1.2.1. Route of administration segment outlook
2.1.2.2. Product type segment outlook
2.1.2.3. Application segment outlook
2.1.2.4. Modules segment outlook
2.1.2.5. Sales channel segment outlook
2.1.3. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Rising aging population and government-led healthcare spending surge
3.3.1.2. Growing consumer awareness and demand
3.3.1.3. Hospital-based nutrition therapy programs driving FSMP penetration
3.3.1.4. Regulatory priority and fast-track approval for FSMPs targeting rare diseases
3.3.2. Market Restraint Analysis
3.3.2.1. High regulatory barriers and lengthy product approval process
3.3.2.2. Scarcity of Specialized Products for Rare Diseases
3.4. Pricing analysis
3.5. User perspective analysis
3.5.1. Consumer Behavior Analysis
3.6. Technology outlook
3.7. Regulatory framework
3.7.1. Reimbursement framework
3.7.2. Standards, compliance & safety
3.8. Business Environment Analysis Tools
3.8.1. Porter’s five forces analysis
3.8.1.1. Competitive rivalry
3.8.1.2. Threat of new entrants
3.8.1.3. Bargaining power of buyers
3.8.1.4. Bargaining power of suppliers
3.8.1.5. Threat of substitutes
3.8.2. PESTEL Analysis
3.8.2.1. Political landscape
3.8.2.2. Economic and social landscape
3.8.2.3. Technological landscape
3.8.2.4. Environmental landscape
3.8.3. COVID 19 Impact Analysis
CHAPTER 4. CHINA FSMP MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
4.1. China FSMP Market: Route of Administration Movement Analysis
4.2. China FSMP Market: Route of Administration Segment Dashboard
4.3. Route of Administration Movement & Market Share Analysis, 2024 & 2030
4.4. China FSMP Market Estimates & Forecast, by Route of Administration
4.5. Oral
4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
4.6. Enteral
4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 5. CHINA FSMP MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. China FSMP Market: Product Movement Analysis
5.2. China FSMP Market: Product Segment Dashboard
5.3. Product Type Movement & Market Share Analysis, 2024 & 2030
5.4. China FSMP Market Estimates & Forecast, by Product Type
5.5. Pills
5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
5.6. Powder
5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
5.7. Liquid
5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
5.8. Others (semisolid, semiliquid)
5.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 6. CHINA FSMP MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. China FSMP Market: Application Movement Analysis
6.2. China FSMP Market: Application Segment Dashboard
6.3. Filter Movement & Market Share Analysis, 2024 & 2030
6.4. China FSMP Market Estimates & Forecast, by Filter
6.5. Chronic Kidney Disease
6.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.6. Minimal Hepatic Encephalopathy
6.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.7. Chemotherapy Induced Diarrhea
6.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.8. Pathogen Related Infections
6.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.9. Diabetic Neuropathy
6.9.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.10. ADHD
6.10.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.11. Depression
6.11.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.12. Alzheimer's Disease
6.12.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.13. Nutritional Deficiency
6.13.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14. Orphan Diseases
6.14.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.2. Tyrosinemia
6.14.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.3. Eosinophilic Esophagitis
6.14.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.4. Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES))
6.14.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.5. Phenylketonuria (PKU)
6.14.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.6. Maple syrup urine disease (Maple syrup urine disease (MSUD))
6.14.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.7. Homocystinuria
6.14.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.8. Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc.)
6.14.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.15. Wound Healing
6.15.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.16. Chronic Diarrhea
6.16.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.17. Constipation Relief
6.17.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.18. Protein Booster
6.18.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.19. Dysphagia
6.19.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.20. Pain Management
6.20.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.21. Parkinson's Disease
6.21.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.22. Epilepsy
6.22.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.23. Other Cancer related treatments
6.23.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.24. Severe Protein Allergy
6.24.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.25. Cancer
6.25.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.26. Cachexia
6.26.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.27. Other (debilitating conditions, COPD, etc.)
6.27.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 7. CHINA FSMP MARKET: MODULES ESTIMATES & TREND ANALYSIS
7.1. China FSMP Market: Modules Movement Analysis
7.2. China FSMP Market: Modules Segment Dashboard
7.3. Modules Movement & Market Share Analysis, 2024 & 2030
7.4. China FSMP Market Estimates & Forecast, by Modules
7.5. Amino Acid Module
7.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.6. Protein Module
7.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.7. Vitamin & Mineral Modules
7.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.8. Fatty Acid based Modules
7.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.9. Carbohydrate Modules
7.9.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.10. Fiber Modules
7.10.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.11. Ketogenic Modules
7.11.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.12. Peptide based Modules
7.12.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.13. Hypoallergic Modules
7.13.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.14. Others (Electrolyte Module, etc.)
7.14.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 8. CHINA FSMP MARKET: SALES CHANNEL ESTIMATES & TREND ANALYSIS
8.1. China FSMP Market: Sales Channel Movement Analysis
8.2. China FSMP Market: Sales Channel Segment Dashboard
8.3. Sales Channel Movement & Market Share Analysis, 2024 & 2030
8.4. China FSMP Market Estimates & Forecast, by Sales Channel
8.5. DTC Sales Channel
8.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.5.2. Online Sales
8.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.5.3. Retail Sales
8.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.6. Institutional Sales
8.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.6.2. Hospitals
8.6.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.6.3. Others (Long-term Care Facilities, etc.)
8.6.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Company Categorization
9.2. Company Market Position Analysis
9.3. Company Share Analysis
9.4. Company Profiles/Listing
9.4.1. Nutricia (Danone)
9.4.1.1. Overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Nestl?
9.4.2.1. Overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Abbott
9.4.3.1. Overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Fresenius Kabi AG
9.4.4.1. Overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Mead Johnson (Reckitt Benckiser)
9.4.5.1. Overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Maifu Nutrition technology
9.4.6.1. Overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
9.4.7.1. Overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. H&H Group (Biostime)
9.4.8.1. Overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Synutra, Inc.
9.4.9.1. Overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Beingmate global
9.4.10.1. Overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. Taicang Puyuan Pharmaceutical Co
9.4.11.1. Overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives
9.4.12. Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
9.4.12.1. Overview
9.4.12.2. Financial performance
9.4.12.3. Product benchmarking
9.4.12.4. Strategic initiatives
9.4.13. Kunyu Health Pharmaceutical Jiangsu Co., Ltd.
9.4.13.1. Overview
9.4.13.2. Financial performance
9.4.13.3. Product benchmarking
9.4.13.4. Strategic initiatives
9.4.14. Shijiazhuang Junlebao Taixing Dairy Co., Ltd., Jiangsu
9.4.14.1. Overview
9.4.14.2. Financial performance
9.4.14.3. Product benchmarking
9.4.14.4. Strategic initiatives
9.4.15. Jiangsu Dongze Special Medical Food Co., Ltd.
9.4.15.1. Overview
9.4.15.2. Financial performance
9.4.15.3. Product benchmarking
9.4.15.4. Strategic initiatives
9.4.16. Heilongjiang Feihe Dairy Co., Ltd.
9.4.16.1. Overview
9.4.16.2. Financial performance
9.4.16.3. Product benchmarking
9.4.16.4. Strategic initiatives
9.4.17. Ainuo Instrument Co., Ltd.
9.4.17.1. Overview
9.4.17.2. Financial performance
9.4.17.3. Product benchmarking
9.4.17.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.6. Research Assumption
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. Objectives
1.8.1. Objective - 1
1.8.2. Objective - 2
1.8.3. Objective - 3
1.9. List of Secondary Sources
1.10. List of Secondary Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. China FSMP Market
2.1.1. Market Snapshot
2.1.2. Segment Snapshot
2.1.2.1. Route of administration segment outlook
2.1.2.2. Product type segment outlook
2.1.2.3. Application segment outlook
2.1.2.4. Modules segment outlook
2.1.2.5. Sales channel segment outlook
2.1.3. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Rising aging population and government-led healthcare spending surge
3.3.1.2. Growing consumer awareness and demand
3.3.1.3. Hospital-based nutrition therapy programs driving FSMP penetration
3.3.1.4. Regulatory priority and fast-track approval for FSMPs targeting rare diseases
3.3.2. Market Restraint Analysis
3.3.2.1. High regulatory barriers and lengthy product approval process
3.3.2.2. Scarcity of Specialized Products for Rare Diseases
3.4. Pricing analysis
3.5. User perspective analysis
3.5.1. Consumer Behavior Analysis
3.6. Technology outlook
3.7. Regulatory framework
3.7.1. Reimbursement framework
3.7.2. Standards, compliance & safety
3.8. Business Environment Analysis Tools
3.8.1. Porter’s five forces analysis
3.8.1.1. Competitive rivalry
3.8.1.2. Threat of new entrants
3.8.1.3. Bargaining power of buyers
3.8.1.4. Bargaining power of suppliers
3.8.1.5. Threat of substitutes
3.8.2. PESTEL Analysis
3.8.2.1. Political landscape
3.8.2.2. Economic and social landscape
3.8.2.3. Technological landscape
3.8.2.4. Environmental landscape
3.8.3. COVID 19 Impact Analysis
CHAPTER 4. CHINA FSMP MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
4.1. China FSMP Market: Route of Administration Movement Analysis
4.2. China FSMP Market: Route of Administration Segment Dashboard
4.3. Route of Administration Movement & Market Share Analysis, 2024 & 2030
4.4. China FSMP Market Estimates & Forecast, by Route of Administration
4.5. Oral
4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
4.6. Enteral
4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 5. CHINA FSMP MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. China FSMP Market: Product Movement Analysis
5.2. China FSMP Market: Product Segment Dashboard
5.3. Product Type Movement & Market Share Analysis, 2024 & 2030
5.4. China FSMP Market Estimates & Forecast, by Product Type
5.5. Pills
5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
5.6. Powder
5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
5.7. Liquid
5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
5.8. Others (semisolid, semiliquid)
5.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 6. CHINA FSMP MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. China FSMP Market: Application Movement Analysis
6.2. China FSMP Market: Application Segment Dashboard
6.3. Filter Movement & Market Share Analysis, 2024 & 2030
6.4. China FSMP Market Estimates & Forecast, by Filter
6.5. Chronic Kidney Disease
6.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.6. Minimal Hepatic Encephalopathy
6.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.7. Chemotherapy Induced Diarrhea
6.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.8. Pathogen Related Infections
6.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.9. Diabetic Neuropathy
6.9.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.10. ADHD
6.10.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.11. Depression
6.11.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.12. Alzheimer's Disease
6.12.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.13. Nutritional Deficiency
6.13.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14. Orphan Diseases
6.14.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.2. Tyrosinemia
6.14.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.3. Eosinophilic Esophagitis
6.14.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.4. Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES))
6.14.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.5. Phenylketonuria (PKU)
6.14.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.6. Maple syrup urine disease (Maple syrup urine disease (MSUD))
6.14.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.7. Homocystinuria
6.14.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.14.8. Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc.)
6.14.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.15. Wound Healing
6.15.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.16. Chronic Diarrhea
6.16.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.17. Constipation Relief
6.17.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.18. Protein Booster
6.18.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.19. Dysphagia
6.19.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.20. Pain Management
6.20.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.21. Parkinson's Disease
6.21.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.22. Epilepsy
6.22.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.23. Other Cancer related treatments
6.23.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.24. Severe Protein Allergy
6.24.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.25. Cancer
6.25.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.26. Cachexia
6.26.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
6.27. Other (debilitating conditions, COPD, etc.)
6.27.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 7. CHINA FSMP MARKET: MODULES ESTIMATES & TREND ANALYSIS
7.1. China FSMP Market: Modules Movement Analysis
7.2. China FSMP Market: Modules Segment Dashboard
7.3. Modules Movement & Market Share Analysis, 2024 & 2030
7.4. China FSMP Market Estimates & Forecast, by Modules
7.5. Amino Acid Module
7.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.6. Protein Module
7.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.7. Vitamin & Mineral Modules
7.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.8. Fatty Acid based Modules
7.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.9. Carbohydrate Modules
7.9.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.10. Fiber Modules
7.10.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.11. Ketogenic Modules
7.11.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.12. Peptide based Modules
7.12.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.13. Hypoallergic Modules
7.13.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
7.14. Others (Electrolyte Module, etc.)
7.14.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 8. CHINA FSMP MARKET: SALES CHANNEL ESTIMATES & TREND ANALYSIS
8.1. China FSMP Market: Sales Channel Movement Analysis
8.2. China FSMP Market: Sales Channel Segment Dashboard
8.3. Sales Channel Movement & Market Share Analysis, 2024 & 2030
8.4. China FSMP Market Estimates & Forecast, by Sales Channel
8.5. DTC Sales Channel
8.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.5.2. Online Sales
8.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.5.3. Retail Sales
8.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.6. Institutional Sales
8.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.6.2. Hospitals
8.6.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
8.6.3. Others (Long-term Care Facilities, etc.)
8.6.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Company Categorization
9.2. Company Market Position Analysis
9.3. Company Share Analysis
9.4. Company Profiles/Listing
9.4.1. Nutricia (Danone)
9.4.1.1. Overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Nestl?
9.4.2.1. Overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Abbott
9.4.3.1. Overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Fresenius Kabi AG
9.4.4.1. Overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Mead Johnson (Reckitt Benckiser)
9.4.5.1. Overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Maifu Nutrition technology
9.4.6.1. Overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
9.4.7.1. Overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. H&H Group (Biostime)
9.4.8.1. Overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Synutra, Inc.
9.4.9.1. Overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Beingmate global
9.4.10.1. Overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. Taicang Puyuan Pharmaceutical Co
9.4.11.1. Overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives
9.4.12. Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
9.4.12.1. Overview
9.4.12.2. Financial performance
9.4.12.3. Product benchmarking
9.4.12.4. Strategic initiatives
9.4.13. Kunyu Health Pharmaceutical Jiangsu Co., Ltd.
9.4.13.1. Overview
9.4.13.2. Financial performance
9.4.13.3. Product benchmarking
9.4.13.4. Strategic initiatives
9.4.14. Shijiazhuang Junlebao Taixing Dairy Co., Ltd., Jiangsu
9.4.14.1. Overview
9.4.14.2. Financial performance
9.4.14.3. Product benchmarking
9.4.14.4. Strategic initiatives
9.4.15. Jiangsu Dongze Special Medical Food Co., Ltd.
9.4.15.1. Overview
9.4.15.2. Financial performance
9.4.15.3. Product benchmarking
9.4.15.4. Strategic initiatives
9.4.16. Heilongjiang Feihe Dairy Co., Ltd.
9.4.16.1. Overview
9.4.16.2. Financial performance
9.4.16.3. Product benchmarking
9.4.16.4. Strategic initiatives
9.4.17. Ainuo Instrument Co., Ltd.
9.4.17.1. Overview
9.4.17.2. Financial performance
9.4.17.3. Product benchmarking
9.4.17.4. Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 China FSMP market revenue estimates and forecast, by route of administration, 2018 - 2030 (USD Million)
Table 4 China FSMP market revenue estimates and forecast, by product type, 2018 - 2030 (USD Million)
Table 5 China FSMP market revenue estimates and forecast, by application, 2018 - 2030 (USD Million)
Table 6 China FSMP market revenue estimates and forecast, by modules, 2018 - 2030 (USD Million)
Table 7 China FSMP market revenue estimates and forecast, by sales channel, 2018 - 2030 (USD Million)
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 China FSMP market revenue estimates and forecast, by route of administration, 2018 - 2030 (USD Million)
Table 4 China FSMP market revenue estimates and forecast, by product type, 2018 - 2030 (USD Million)
Table 5 China FSMP market revenue estimates and forecast, by application, 2018 - 2030 (USD Million)
Table 6 China FSMP market revenue estimates and forecast, by modules, 2018 - 2030 (USD Million)
Table 7 China FSMP market revenue estimates and forecast, by sales channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 China FSMP Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for Market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Technology segment outlook
Fig. 11 Application segment outlook
Fig. 12 End Use segment outlook
Fig. 13 Competitive landscape
Fig. 14 China FSMP Market: Market dynamics
Fig. 15 China FSMP Market: Porter’s analysis
Fig. 16 China FSMP Market: PESTLE analysis
Fig. 17 China FSMP Market: Route of administration segment dashboard
Fig. 18 China FSMP Market: Route of administration movement share analysis
Fig. 19 Oral Market, 2018 - 2030 (USD Million, Unit Volume)
Fig. 20 Enteral Market, 2018 - 2030 (USD Million, Unit Volume)
Fig. 21 China FSMP Market: Product segment dashboard
Fig. 22 China FSMP Market: Product Movement Share Analysis
Fig. 23 Pills Market, 2018 - 2030 (USD Million)
Fig. 24 Powder Market, 2018 - 2030 (USD Million)
Fig. 25 Liquid Market, 2018 - 2030 (USD Million)
Fig. 26 Others (semisolid, semiliquid) Market, 2018 - 2030 (USD Million)
Fig. 27 China FSMP Market: Application Segment Dashboard
Fig. 28 China FSMP Market: Application Movement Share Analysis
Fig. 29 Chronic Kidney Disease Market, 2018 - 2030 (USD Million)
Fig. 30 Minimal Hepatic Encephalopathy Market, 2018 - 2030 (USD Million)
Fig. 31 Chemotherapy Induced Diarrhoea Market, 2018 - 2030 (USD Million)
Fig. 32 Pathogen Related Infections Market, 2018 - 2030 (USD Million)
Fig. 33 Diabetic Neuropathy Market, 2018 - 2030 (USD Million)
Fig. 34 ADHD Market, 2018 - 2030 (USD Million)
Fig. 35 Depression Market, 2018 - 2030 (USD Million)
Fig. 36 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
Fig. 37 Nutritional Deficiency Market, 2018 - 2030 (USD Million)
Fig. 38 Orphan Diseases Market, 2018 - 2030 (USD Million)
Fig. 39 Tyrosinemia Market, 2018 - 2030 (USD Million)
Fig. 40 Eosinophilic Esophagitis Market, 2018 - 2030 (USD Million)
Fig. 41 Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES)) Market, 2018 - 2030 (USD Million)
Fig. 42 Phenylketonuria (PKU) Market, 2018 - 2030 (USD Million)
Fig. 43 Maple syrup urine disease (Maple syrup urine disease (MSUD)) Market, 2018 - 2030 (USD Million)
Fig. 44 Homocystinuria Market, 2018 - 2030 (USD Million)
Fig. 45 Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc) Market, 2018 - 2030 (USD Million)
Fig. 46 Wound Healing Market, 2018 - 2030 (USD Million)
Fig. 47 Chronic Diarrhea Market, 2018 - 2030 (USD Million)
Fig. 48 Constipation Relief Market, 2018 - 2030 (USD Million)
Fig. 49 Protein Booster Market, 2018 - 2030 (USD Million)
Fig. 50 Dysphagia Market, 2018 - 2030 (USD Million)
Fig. 51 Pain Management Market, 2018 - 2030 (USD Million)
Fig. 52 Parkinson's Disease Market, 2018 - 2030 (USD Million)
Fig. 53 Epilepsy Market, 2018 - 2030 (USD Million)
Fig. 54 Other Cancer related treatments Market, 2018 - 2030 (USD Million)
Fig. 55 Severe Protein Allergy Market, 2018 - 2030 (USD Million)
Fig. 56 Cancer Market, 2018 - 2030 (USD Million)
Fig. 57 Cachexia Market, 2018 - 2030 (USD Million)
Fig. 58 Other (debilitating conditions, COPD, etc) Market, 2018 - 2030 (USD Million)
Fig. 59 China FSMP Market: Modules Segment Dashboard
Fig. 60 China FSMP Market: Modules Movement Share Analysis
Fig. 61 Amino Acid Module Market, 2018 - 2030 (USD Million)
Fig. 62 Protein Module Market, 2018 - 2030 (USD Million)
Fig. 63 Vitamin & Mineral Modules Market, 2018 - 2030 (USD Million)
Fig. 64 Fatty Acid based Modules Market, 2018 - 2030 (USD Million)
Fig. 65 Carbohydrate Modules Market, 2018 - 2030 (USD Million)
Fig. 66 Fiber Modules Market, 2018 - 2030 (USD Million)
Fig. 67 Ketogenic Modules Market, 2018 - 2030 (USD Million)
Fig. 68 Peptide based Modules Market, 2018 - 2030 (USD Million)
Fig. 69 Hypoallergic Modules Market, 2018 - 2030 (USD Million)
Fig. 70 Others (Electrolyte Module, etc) Market, 2018 - 2030 (USD Million)
Fig. 71 China FSMP Market: Sales Channel Segment Dashboard
Fig. 72 China FSMP Market: Sales Channel Movement Share Analysis
Fig. 73 DTC Sales Channel Market, 2018 - 2030 (USD Million)
Fig. 74 Online Sales Market, 2018 - 2030 (USD Million)
Fig. 75 Retail Sales Market, 2018 - 2030 (USD Million)
Fig. 76 Institutional Sales Market, 2018 - 2030 (USD Million)
Fig. 77 Hospitals Market, 2018 - 2030 (USD Million)
Fig. 78 Others (Long-term Care Facilities, etc) Market, 2018 - 2030 (USD Million)
Fig. 79 Company categorization
Fig. 80 Company Market position analysis
Fig. 81 Strategic framework
Fig. 1 China FSMP Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for Market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Technology segment outlook
Fig. 11 Application segment outlook
Fig. 12 End Use segment outlook
Fig. 13 Competitive landscape
Fig. 14 China FSMP Market: Market dynamics
Fig. 15 China FSMP Market: Porter’s analysis
Fig. 16 China FSMP Market: PESTLE analysis
Fig. 17 China FSMP Market: Route of administration segment dashboard
Fig. 18 China FSMP Market: Route of administration movement share analysis
Fig. 19 Oral Market, 2018 - 2030 (USD Million, Unit Volume)
Fig. 20 Enteral Market, 2018 - 2030 (USD Million, Unit Volume)
Fig. 21 China FSMP Market: Product segment dashboard
Fig. 22 China FSMP Market: Product Movement Share Analysis
Fig. 23 Pills Market, 2018 - 2030 (USD Million)
Fig. 24 Powder Market, 2018 - 2030 (USD Million)
Fig. 25 Liquid Market, 2018 - 2030 (USD Million)
Fig. 26 Others (semisolid, semiliquid) Market, 2018 - 2030 (USD Million)
Fig. 27 China FSMP Market: Application Segment Dashboard
Fig. 28 China FSMP Market: Application Movement Share Analysis
Fig. 29 Chronic Kidney Disease Market, 2018 - 2030 (USD Million)
Fig. 30 Minimal Hepatic Encephalopathy Market, 2018 - 2030 (USD Million)
Fig. 31 Chemotherapy Induced Diarrhoea Market, 2018 - 2030 (USD Million)
Fig. 32 Pathogen Related Infections Market, 2018 - 2030 (USD Million)
Fig. 33 Diabetic Neuropathy Market, 2018 - 2030 (USD Million)
Fig. 34 ADHD Market, 2018 - 2030 (USD Million)
Fig. 35 Depression Market, 2018 - 2030 (USD Million)
Fig. 36 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
Fig. 37 Nutritional Deficiency Market, 2018 - 2030 (USD Million)
Fig. 38 Orphan Diseases Market, 2018 - 2030 (USD Million)
Fig. 39 Tyrosinemia Market, 2018 - 2030 (USD Million)
Fig. 40 Eosinophilic Esophagitis Market, 2018 - 2030 (USD Million)
Fig. 41 Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES)) Market, 2018 - 2030 (USD Million)
Fig. 42 Phenylketonuria (PKU) Market, 2018 - 2030 (USD Million)
Fig. 43 Maple syrup urine disease (Maple syrup urine disease (MSUD)) Market, 2018 - 2030 (USD Million)
Fig. 44 Homocystinuria Market, 2018 - 2030 (USD Million)
Fig. 45 Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc) Market, 2018 - 2030 (USD Million)
Fig. 46 Wound Healing Market, 2018 - 2030 (USD Million)
Fig. 47 Chronic Diarrhea Market, 2018 - 2030 (USD Million)
Fig. 48 Constipation Relief Market, 2018 - 2030 (USD Million)
Fig. 49 Protein Booster Market, 2018 - 2030 (USD Million)
Fig. 50 Dysphagia Market, 2018 - 2030 (USD Million)
Fig. 51 Pain Management Market, 2018 - 2030 (USD Million)
Fig. 52 Parkinson's Disease Market, 2018 - 2030 (USD Million)
Fig. 53 Epilepsy Market, 2018 - 2030 (USD Million)
Fig. 54 Other Cancer related treatments Market, 2018 - 2030 (USD Million)
Fig. 55 Severe Protein Allergy Market, 2018 - 2030 (USD Million)
Fig. 56 Cancer Market, 2018 - 2030 (USD Million)
Fig. 57 Cachexia Market, 2018 - 2030 (USD Million)
Fig. 58 Other (debilitating conditions, COPD, etc) Market, 2018 - 2030 (USD Million)
Fig. 59 China FSMP Market: Modules Segment Dashboard
Fig. 60 China FSMP Market: Modules Movement Share Analysis
Fig. 61 Amino Acid Module Market, 2018 - 2030 (USD Million)
Fig. 62 Protein Module Market, 2018 - 2030 (USD Million)
Fig. 63 Vitamin & Mineral Modules Market, 2018 - 2030 (USD Million)
Fig. 64 Fatty Acid based Modules Market, 2018 - 2030 (USD Million)
Fig. 65 Carbohydrate Modules Market, 2018 - 2030 (USD Million)
Fig. 66 Fiber Modules Market, 2018 - 2030 (USD Million)
Fig. 67 Ketogenic Modules Market, 2018 - 2030 (USD Million)
Fig. 68 Peptide based Modules Market, 2018 - 2030 (USD Million)
Fig. 69 Hypoallergic Modules Market, 2018 - 2030 (USD Million)
Fig. 70 Others (Electrolyte Module, etc) Market, 2018 - 2030 (USD Million)
Fig. 71 China FSMP Market: Sales Channel Segment Dashboard
Fig. 72 China FSMP Market: Sales Channel Movement Share Analysis
Fig. 73 DTC Sales Channel Market, 2018 - 2030 (USD Million)
Fig. 74 Online Sales Market, 2018 - 2030 (USD Million)
Fig. 75 Retail Sales Market, 2018 - 2030 (USD Million)
Fig. 76 Institutional Sales Market, 2018 - 2030 (USD Million)
Fig. 77 Hospitals Market, 2018 - 2030 (USD Million)
Fig. 78 Others (Long-term Care Facilities, etc) Market, 2018 - 2030 (USD Million)
Fig. 79 Company categorization
Fig. 80 Company Market position analysis
Fig. 81 Strategic framework
